Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis.

Alhassane Diallo, Miguel Carlos-Bolumbu, Minerva Cervantes-Gonzalez, Veronika Wozniak, Mamadou Hassimiou Diallo, Boubacar Djelo Diallo, Alexandre Delamou, Florence Galtier

Human vaccines & immunotherapeutics 2021 Oct 03

filter terms:

Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety. A total of 21 randomized controlled trial, evaluating seven different vaccines with different doses, and 5,275 participants were analyzed. The rVSVΔG-ZEBOV-GP (2 × 10 7) vaccine was more immunogenic (P-score 0.80). For pain, rVSVΔG-ZEBOV-GP (≤10 5) had few events (P-score 0.90). For fatigue and headache, the DNA-EBOV (≤ 4 mg) was the best one with P-scores of 0.94 and 0.87, respectively. For myalgia, the ChAd3 (10 10) had a lower risk (P-score 0.94). For fever, the Ad5.ZEBOV (≤ 8 × 10 10) was the best one (P-score 0.80). The best vaccine to be used to stop future outbreak of Ebola is the rVSVDG-ZEBOV-GP vaccine at dose of 2 × 107 PFU.

Citation

Alhassane Diallo, Miguel Carlos-Bolumbu, Minerva Cervantes-Gonzalez, Veronika Wozniak, Mamadou Hassimiou Diallo, Boubacar Djelo Diallo, Alexandre Delamou, Florence Galtier. Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis. Human vaccines & immunotherapeutics. 2021 Oct 03;17(10):3771-3783